We have recently reported that in human neuroblastoma cells valproic acid (VPA), a preferential inhibitor of HDACs belonging to class I and IIa [3], and other HDAC inhibitors favorably alter neurotrophin receptor expression and signaling. The gene discussed is HDAC9; the disease is neuroblastoma.